| IVZ |
Report |
Net Revenues — Operating (2Q2026) |
BEAT |
pred ~$1,360M vs. cons $1,332M |
MEDIUM |
| IVZ |
Report |
EPS — Diluted Operating (2Q2026) |
BEAT |
pred ~$0.68 vs. cons $0.662 |
MEDIUM |
| IVZ |
Report |
Long-Term Net Flows (2Q2026) |
IN-LINE |
pred ~$45.2B vs. cons $44.97B |
HIGH |
| IVZ |
Guide |
FY2026 Opex (FY2026) |
UNCHANGED |
guide ~$3.35-3.40B vs. cons $3.378B |
MEDIUM |
| IVZ |
Guide |
FY2026 EPS implied (FY2026) |
UNCHANGED |
guide ~$2.85-2.90 vs. cons $2.850 |
MEDIUM |
| IVZ |
Guide |
Net Revenue Yield tone (2Q2026 exit) |
UNCHANGED |
acknowledge compression to ~22.3-22.5 bps; redirect to margin |
MEDIUM |
| IVZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.8% |
— |
MEDIUM |
| IVZ |
Return |
5-day cumulative residual |
+1.2% (STABILIZE) |
STABILIZE — short covering provides modest follow-through; yield compression narrative caps upside; no estimate revision catalyst without a formal raise |
MEDIUM |